Dr Reddy's Laboratories Ltd
SWB:RDDA

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
SWB:RDDA
Watchlist
Price: 11.6 EUR -0.85%
Market Cap: 1.9B EUR
Section:
 

Relative Value

The Relative Value of one RDDA stock under the Base Case scenario is hidden EUR. Compared to the current market price of 11.6 EUR, Dr Reddy's Laboratories Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RDDA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.9
P/S
P/S
Price to Sales
2.9
vs History
46
vs Industry
36
Median 3Y
3.2
Median 5Y
2.9
Industry
2.6
Forward
2.9
More Details
17.4
P/E
P/E
Price to Earnings
17.4
vs History
36
vs Industry
26
Median 3Y
18.1
Median 5Y
16.9
Industry
21.4
Forward
18.9
More Details
17.1
P/OCF
P/OCF
Price to OCF
17.1
vs History
33
vs Industry
15
Median 3Y
17.7
Median 5Y
12.5
Industry
16.4
More Details
72.5
P/FCFE
P/FCFE
Price to FCFE
72.5
vs History
9
vs Industry
18
Median 3Y
31.9
Median 5Y
23.8
Industry
22.8
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
52
vs Industry
23
Median 3Y
3.3
Median 5Y
2.9
Industry
2.2
More Details
2.7
EV/S
EV/S
Enterprise Value to Sales
2.7
vs History
42
vs Industry
38
Median 3Y
3
Median 5Y
2.8
Industry
2.9
Forward
2.7
More Details
4.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.1
vs History
41
vs Industry
47
Median 3Y
4.4
Median 5Y
4
Industry
5.5
More Details
10.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.9
vs History
33
vs Industry
30
Median 3Y
11.3
Median 5Y
10.4
Industry
13
Forward
11.3
More Details
14
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14
vs History
19
vs Industry
31
Median 3Y
13.9
Median 5Y
12.7
Industry
16.5
Forward
14.7
More Details
16
EV/OCF
EV/OCF
Enterprise Value to OCF
16
vs History
33
vs Industry
16
Median 3Y
16.7
Median 5Y
11.6
Industry
15.6
More Details
51
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
51
vs History
28
vs Industry
4
Median 3Y
51.8
Median 5Y
17
Industry
18.7
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
50
vs Industry
30
Median 3Y
2.7
Median 5Y
2.3
Industry
1.9
More Details

Multiples Across Competitors

RDDA Competitors Multiples
Dr Reddy's Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Dr Reddy's Laboratories Ltd
SWB:RDDA
1T EUR 2.9 17.4 10.9 14
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.9 38.1 40.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.3B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
269.9B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
220.1B GBP 5.1 31.5 108.7 159.1
CH
Novartis AG
SIX:NOVN
218.2B CHF 4.9 19 12 15.5
US
Merck & Co Inc
NYSE:MRK
270.1B USD 4.2 14.2 10.1 11.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
IN
Dr Reddy's Laboratories Ltd
SWB:RDDA
Average P/E: 24.2
17.4
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
56.9
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Dr Reddy's Laboratories Ltd
SWB:RDDA
Average EV/EBITDA: 401.1
10.9
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
38.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Dr Reddy's Laboratories Ltd
SWB:RDDA
Average EV/EBIT: 1 713.7
14
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
40.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
RDDA intrinsic value, competitors valuation, and company profile.
DCF Valuation
RDDA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RDDA stock valuation using valuation multiples.
Wall Street Estimates
RDDA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RDDA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.